{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:24:33Z","timestamp":1768706673026,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clineuro.2025.108875","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T13:50:42Z","timestamp":1743256242000},"page":"108875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan"],"prefix":"10.1016","volume":"252","author":[{"given":"Yuki","family":"Yasutaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayasu","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-6125","authenticated-orcid":false,"given":"Kentaro","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-2964","authenticated-orcid":false,"given":"Akira","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2025.108875_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","article-title":"Description of Parkinson\u2019s disease as a clinical syndrome","volume":"991","author":"Fahn","year":"2003","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.clineuro.2025.108875_bib2","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","article-title":"Levodopa for the treatment of Parkinson's disease","volume":"359","author":"Lewitt","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clineuro.2025.108875_bib3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2025.108875_bib4","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations","author":"Jankovic","year":"2005","journal-title":"Mov. Disord. 20"},{"key":"10.1016\/j.clineuro.2025.108875_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00228-014-1701-2","article-title":"Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations","volume":"70","author":"Rocha","year":"2014","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.clineuro.2025.108875_bib6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/cells11091511","article-title":"Effects of one-day application of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa\/opicapone in Parkinson\u2019s disease patients","volume":"11","author":"M\u00fcller","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.clineuro.2025.108875_bib7","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.29193","article-title":"Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson's disease","volume":"37","author":"Ferreira","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.clineuro.2025.108875_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","article-title":"Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial","volume":"15","author":"Ferreira","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2025.108875_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00702-021-02315-1","article-title":"Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations","volume":"128","author":"Takeda","year":"2021","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.clineuro.2025.108875_bib10","doi-asserted-by":"crossref","first-page":"e1849","DOI":"10.1212\/WNL.0000000000005557","article-title":"P, Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease","volume":"90","author":"Ferreira","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2025.108875_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mdc3.14030","article-title":"Opicapone to treat early wearing-off in Parkinson's disease patients: the Korean ADOPTION trial","volume":"11","author":"Lee","year":"2024","journal-title":"Mov. Disord. Clin. Pr."},{"key":"10.1016\/j.clineuro.2025.108875_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mdc3.13094","article-title":"Opicapone efficacy and tolerability in Parkinson's disease patients reporting insufficient benefit\/failure of entacapone","volume":"7","author":"Vokurka","year":"2020","journal-title":"Mov. Disord. Clin. Pr."},{"key":"10.1016\/j.clineuro.2025.108875_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","article-title":"Opicapone as adjunct to levodopa therapy in patients with parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Lees","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2025.108875_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/13696998.2021.1916750","article-title":"Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa\/carbidopa","volume":"24","author":"Hansen","year":"2021","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.clineuro.2025.108875_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00702-023-02603-y","article-title":"The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone","volume":"30","author":"Leta","year":"2023","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.clineuro.2025.108875_bib16","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/ene.15990","article-title":"Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment","volume":"30","author":"Harrison-Jones","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clineuro.2025.108875_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/cer-2022-0031","article-title":"Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: a systematic review and meta-analysis","volume":"11","author":"\u017begle\u0144","year":"2022","journal-title":"J. Comp. Eff. Res"},{"key":"10.1016\/j.clineuro.2025.108875_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00702-023-02700-y","article-title":"A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates","volume":"131","author":"Metta","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.clineuro.2025.108875_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov. Disord. Clin. Pr."},{"key":"10.1016\/j.clineuro.2025.108875_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.clineuro.2025.108875_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/clpt.1990.166","article-title":"Human liver catechol-O-methyltransferase pharmacogenetics","volume":"48","author":"Boud\u00edkov\u00e1","year":"1990","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.clineuro.2025.108875_bib22","article-title":"J-FIRST Group, Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST","volume":"448","author":"Mishima","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clineuro.2025.108875_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2018.02.012","article-title":"Clinical risk factors for the development of tardive dyskinesia","volume":"389","author":"Solmi","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2025.108875_bib24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/nu15040901","article-title":"Two faces of Catechol-O-methyltransferase inhibitor on one-carbon metabolism in Parkinson's disease: a meta-analysis","volume":"15","author":"Kim","year":"2023","journal-title":"Nutrients"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846725001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T14:15:04Z","timestamp":1768659304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846725001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":24,"alternative-id":["S0303846725001581"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.108875","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors affecting continuation rates of opicapone: A retrospective study at a single center in Japan","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.108875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108875"}}